You are here » Home » Companies » Company Overview » Concord Drugs Ltd

Concord Drugs Ltd.

BSE: 538965 Sector: Health care
NSE: N.A. ISIN Code: INE858L01010
BSE 00:00 | 23 Jul 28.75 0.05
(0.17%)
OPEN

29.30

HIGH

29.90

LOW

27.30

NSE 05:30 | 01 Jan Concord Drugs Ltd
OPEN 29.30
PREVIOUS CLOSE 28.70
VOLUME 35259
52-Week high 44.95
52-Week low 12.65
P/E 62.50
Mkt Cap.(Rs cr) 25
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 29.30
CLOSE 28.70
VOLUME 35259
52-Week high 44.95
52-Week low 12.65
P/E 62.50
Mkt Cap.(Rs cr) 25
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Concord Drugs Ltd. (CONCORDDRUGS) - Director Report

Company director report

To the Members

The Directors have pleasure in presenting before you the 25th Board's Report of theCompany together with the Audited Statements of Accounts for the year ended 31stMarch2020.

1. FINANCIAL SUMMARY/HIGHLIGHTS OPERATIONS STATE OF AFFAIRS:

The performance during the period ended 31st March 2020 has been as under:

Particulars 2019-2020 2018-2019
Revenue from Operations 5133.89 4807.72
Other Income 12.01 8.59
Profit/Loss Before Depreciation finance costs Exceptional Items and Tax expense 346.41 374.46
Less: Depreciation/Amortisation/Impairment 146.39 171.18
Profit/Loss before finance costs exceptional items and Tax expense 200.02 203.28
Less: Finance Costs 154.37 159.30
Profit/Loss before Exceptional Items and Finance Costs 45.65 43.98
Add/(Less): Exceptional Items Nil Nil
Profit/Loss before tax expense 45.65 43.98
(Less): Tax Expense (Current & deferred) 12.82 3.27
Profit/(Loss) for the year (1) 32.83 40.70
Total Comprehensive Income/(Loss) (2) Nil Nil
Total (1+2) 32.83 40.70
Balance carried forward to balance sheet 32.83 40.70
Earnings per share 0.38 0.52

REVIEW OF OPERATIONS:

During the year the Company has generated a revenue of Rs. 5133.89 lakhs and achieveda profit of Rs. 32.83 lakhs for the financial year 2019-20 as against the revenue of Rs.4807.72 Lakhs and net profit of Rs. 40.70 lakhs for the previous year.

IMPACT OF COVID 19

The company has evaluated the impact of Corona Virus (COVID-19) on the operations andfuture economic activity of the company and based on its review and current indicators andfuture economic prospects there is no significant impact on the business of the companyor its operations.

However in the initial days of Lockdown in March the companies manufacturingactivities were impacted to minimal extent as the majority of employees could not reachthe factory location due to the restrictions on movement of manpower unavailability ofTransportation.

2. MATERIAL CHANGES AND COMMITMENTS:

There were no material changes and commitments affecting financial position of thecompany between 31st March and the date of Board's Report. (i.e. 27.06.2020)

3. CHANGE IN THE NATURE OF BUSINESS IF ANY:

During the period under review and the date of Board's Report there was no change inthe nature of Business.

4. DIVIDEND:

The Directors have not recommended any dividend for the year.

UNPAID / UNCLAIMED DIVIDEND:

There is no unpaid or unclaimed dividend with the company.

5. RESERVES:

The Company has not carried any amount to the reserves.

6. BOARD MEETINGS:

The Board of Directors duly met 7 (seven) times on 16.04.2019 14.05.2019 30.05.201914.08.2019 15.10.2019 14.11.2019 and 13.02.2020 and in respect of which meetings propernotices were given and the proceedings were properly recorded and signed in the MinutesBook maintained for the purpose.

7. REVISION OF FINANCIAL STATEMENTS

There was no revision of the financial statements for the year under review.

8. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS

The company has received declarations from Independent directors of the company to theeffect that they are meeting the criteria of independence as provided in Sub-section (6)of Section 149 of the Companies Act 2013 and Regulation 25 of SEBI (Listing Obligationsand Disclosure Requirement) Regulations 2015.

The Independent Directors have also confirmed that they have complied Company's Code ofConduct. In terms of Regulations 25(8) of the Listing Regulations the IndependentDirectors have confirmed that they are not aware of any circumstance or situation whichexists or may be reasonably anticipated that could impair or impact their ability todischarge their duties with an objective independent judgement and without any externalinfluence.

9. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/CFO AND KEY MANANGERIAL PERSONNEL.

During the year Mrs. P. Chandrakala was reappointed as Independent Director subject tothe approval by shareholders of the company at the general meeting after considering therecommendations of the Nomination and Remuneration Committee. Mr. Thati Narsimha Reddy andMr. S. Nagi Reddy were appointed as Managing Director and Wholetime Director respectivelyfor the term of 3 years. Mr. S. Koni Reddy who was liable to rotation has offered himselffor the Appointment.

During the year under review the Company has resigned Ms. Monika Bhutada as CompanySecretary and Compliance Officer at the Board meeting held on 16th April 2019. Ms. JyotiGoyal was appointed as Company Secretary and Compliance Officer at the Board meeting heldon 15th October 2019.

10. FAMILIARISATION PROGRAMMES:

The Company familiarises its Independent Directors on their appointment as such on theBoard with the Company their roles rights responsibilities in the Company nature ofthe industry in which the Company operates etc. through familiarisation programme. TheCompany also conducts orientation programme upon induction of new Directors as well asother initiatives to update the Directors on a continuing basis. The familiarisationprogramme for Independent Directors is disclosed on the Company's websitewww.concorddrugs.in.

11. COMPOSITION OF AUDIT COMMITTEE:

I. The Audit Committee of the Company is constituted in line with the provisions ofRegulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015read with Section 177 of the Companies Act 2013.

II. The terms of reference of the Audit Committee include a review of the following:

• Overview of the Company's financial reporting process and disclosure of itsfinancial information to ensure that the financial statements reflect a true and fairposition and that sufficient and credible information is disclosed.

• Recommending the appointment and removal of external auditors fixation of auditfee and also approval for payment for any other services.

• Discussion with external auditors before the audit commences of the nature andscope of audit as well as post-audit discussion to ascertain any area of concern.

• Reviewing the financial statements and draft audit report including quarterly /half yearly financial information.

• Reviewing with management the annual financial statements before submission tothe Board focusing on:

1. Any changes in accounting policies and practices;

2. Qualification in draft audit report;

3. Significant adjustments arising out of audit;

4. The going concern concept;

5. Compliance with accounting standards;

6. Compliance with stock exchange and legal requirements concerning financialstatements and

7. Any related party transactions

• Reviewing the company's financial and risk management's policies.

• Disclosure of contingent liabilities.

• Reviewing with management external and internal auditors the adequacy ofinternal control systems.

• Reviewing the adequacy of internal audit function including the auditcharacter the structure of the internal audit department approval of the audit plan andits execution staffing and seniority of the official heading the department reportingstructure coverage and frequency of internal audit.

• Discussion with internal auditors of any significant findings and follow-upthereon.

• Reviewing the findings of any internal investigations by the internal auditorsinto the matters where there is suspected fraud or irregularity or a failure of internalcontrol systems of a material nature and reporting the matter to the Board.

• Looking into the reasons for substantial defaults in payments to the depositorsdebenture holders shareholders (in case of non-payment of declared dividends) andcreditors.

• Reviewing compliances as regards the Company's Whistle Blower Policy.

• reviewing the utilization of loans and/ or advances from/investment by theholding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size ofthe subsidiary whichever is lower including existing loans / advances / investments

III. The previous Annual General Meeting of the Company was held on

30.09.2019 and Chairman of the Audit Committee attended previous AGM.

IV. The composition of the Audit Committee and the attendance of each member of theAudit Committee are given below:

During the financial year 2019-20 4 (four) meetings of the Audit Committee were heldon 30.05.2019 14.08.2019 14.11.2019 13.02.2020 respectively.

The details of the composition of the Committee and attendance of the members at themeetings are given below:

Name Designation Category No. of meetings held No. of meeting attended
Ms. P. Chandra Kala Chairman NED(I) 4 4
Mr.S. Nagi Reddy Member ED 4 4
Mr. P. Venkat Ram Reddy Member NED(I) 4 4

NED (I): Non-Executive Independent Director ED: Executive Director

V. NOMINATION & REMUNERATION COMMITTEE

Terms of reference:

The main term of reference of the Committee is to approve the fixation/revision ofremuneration of the Managing Director/Whole Time Director of the Company and whileapproving:

• To take into account the financial position of the Company trend in theindustry appointee's qualification experience past performance past remuneration etc.

• To bring out objectivity in determining the remuneration package while strikinga balance between the interest of the Company and the Shareholders.

• To identify persons who are qualified to become Directors and who may beappointed in senior management in accordance with the criteria laid down and to recommendto the Board their appointment and /or removal.

• To carry out evaluation of every Director's performance.

• To formulate the criteria for determining qualifications positive attributesand independence of a Director and recommend to the Board a policy relating to theremuneration for the Directors key managerial personnel and other employees.

• To formulate the criteria for evaluation of Independent Directors and the Board.

• To recommend/review remuneration of the Managing Director and Whole-timeDirector(s) based on their performance and defined assessment criteria.

• recommend to the board all remuneration in whatever form payable to seniormanagement.

POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER DETAILS:

The assessment and appointment of Members to the Board is based on a combination ofcriterion that includes ethics personal and professional stature domain expertisegender diversity and specific qualification required for the position. The potential BoardMember is also assessed on the basis of independence criteria defined in Section 149(6) ofthe Companies Act 2013 and Regulation 27 of SEBI (LODR) Regulations 2015.

In accordance with Section 178(3) of the Companies Act 2013 and Regulation 19(4) ofSEBI (LODR) Regulations 2015 on the recommendations of the Nomination and RemunerationCommittee the Board adopted a remuneration policy for Directors Key Management Personnel(KMPs) and Senior Management.

Remuneration Policy:

The objectives of the remuneration policy are to motivate Directors to excel in theirperformance recognize their contribution and retain talent in the organization and rewardmerit.

The remuneration levels are governed by industry pattern qualifications and experienceof the Directors responsibilities shouldered individual performance etc.

The details of remuneration paid to the Executive and Non-Executive Directors for thefinancial year 2019-20 are given below:

Mr. S. Nagi Reddy Chairman and Mr. S. Koni Reddy Executive Director have drawn aremuneration of Rs. 1200000 p.a. and Rs. 1200000 p.a. for the year ended 31.03.2020respectively.

None of the Directors is drawing any Commission Perquisites Retirement benefits etc.

During the year the committee met on 16.04.2019 30.05.2019 15.10.2019 and13.02.2020.

The details of composition of the Committee are given below:

Name Designation Category No. of meetings held No. of meeting attended
Ms. P. Chandra Kala Chairman NED(I) 4 4
Mr.S. Nagi Reddy Member ED 4 4
Mr. P. Venkat Ram Reddy Member NED(I) 4 4

NED (I): Non-Executive Independent Director ED: Executive Director

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

1. Scope:

This policy sets out the guiding principles for the Nomination & RemunerationCommittee for identifying persons who are qualified to become Directors and to determinethe independence of Directors in case of their appointment as independent Directors ofthe Company.

2. Terms and References:

2.1 "Director" means a director appointed to the Board of a Company.

1.2 "Nomination and Remuneration Committee means the committee constituted inaccordance with the provisions of Section 178 of the Companies Act 2013 and reg. 19 ofSEBI (Listing Obligation and Disclosure Requirement) Regulations 2015.

2.3 "Independent Director" means a director referred to in sub-section (6) ofSection 149 of the Companies Act 2013 and Regulation 16(1) (b) of the SEBI (Listingobligations and Disclosure Requirements) Regulations 2015.

3. Policy:

Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee and the Board shall review on annualbasis appropriate skills knowledge and experience required of the Board as a whole andits individual members. The objective is to have a board with diverse background andexperience that are relevant for the Company's operations.

3.1.2 In evaluating the suitability of individual Board member the NR Committee maytake into account factors such as:

• General understanding of the company's business dynamics global business andsocial perspective;

• Educational and professional background

• Standing in the profession;

• Personal and professional ethics integrity and values;

• Willingness to devote sufficient time and energy in carrying out their dutiesand responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

• shall possess a Director Identification Number;

• shall not be disqualified under the Companies Act 2013;

• shall Endeavour to attend all Board Meeting and Wherever he is appointed as aCommittee Member the Committee Meeting;

• shall abide by the code of Conduct established by the company for Directors andsenior Management personnel;

• shall disclose his concern or interest in any company or companies or bodiescorporate firms or other association of individuals including his shareholding at thefirst meeting of the Board in every financial year and thereafter whenever there is achange in the disclosures already made;

• Such other requirements as may be prescribed from time to time under theCompanies Act 2013 SEBI (Listing obligations and Disclosure Requirements) Regulations2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual withthe objective of having a group that best enables the success of the company's business.

3.2 Criteria of Independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence ofDirectors at time of appointment/ re-appointment and the Board shall assess the sameannually. The Board shall reassess determinations of independence when any new interest orrelationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with guidelines as laid downin Companies Act 2013 and reg. 16(1) (b) of the SEBI (Listing obligations and DisclosureRequirements) Regulations 2015.

3.2.3 The Independent Director shall abide by the "Code for Independent Directors"as specified in Schedule IV to the companies Act 2013.

10.3 Other Directorships/ Committee Memberships

3.3.1 The Board members are expected to have adequate time and expertise and experienceto contribute to effective Board performance Accordingly members should voluntarily limittheir directorships in other listed public limited companies in such a way that it doesnot interfere with their role as Director of the company. The NR Committee shall take intoaccount the nature of and the time involved in a Director service on other Boards inevaluating the suitability of the individual Director and making its recommendations tothe Board.

3.3.2 A Director shall not serve as director in more than 20 companies of which notmore than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listedcompanies and not more than 3 listed companies in case he is serving as a whole-timeDirector in any listed company.

3.3.4 A Director shall not be a member in more than 10 committee or act chairman ofmore than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee Audit committee andstakeholder's relationship committee of all public limited companies whether listed ornot shall be included and all other companies including private limited companiesforeign companies and companies under section 8 of the Companies Act 2013 shall beexcluded.

Remuneration policy for Directors key managerial personnel and other employees

1. Scope:

1.1 This policy sets out the guiding principles for the Nomination and Remunerationcommittee for recommending to the Board the remuneration of the directors key managerialpersonnel and other employees of the company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

2.1 "Director" means a Director appointed to the Board of the company.

2.2 "key managerial personnel" means

(i) The Chief Executive Office or the managing director or the manager;

(ii) The company secretary;

(iii) The whole-time director;

(iv) The chief finance Officer; and

(v) Such other office as may be prescribed under the companies Act 2013

2.3 "Nomination and Remuneration Committee" means the committee constitutedby Board in accordance with the provisions of section 178 of the companies Act2013 andreg. 19 of SEBI (Listing obligations and Disclosure Requirements) Regulations 2015.

3. Policy:

3.1 Remuneration to Executive Director and Key Managerial Personnel

3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committeeshall review and approve the remuneration payable to the Executive Director of the companywithin the overall approved by the shareholders.

3.1.2 The Board on the recommendation of the NR committee shall also review and approvethe remuneration payable to the key managerial personnel of the company.

3.1.3 The Remuneration structure to the Executive Director and key managerial personnelshall include the following components:

(i) Basic pay

(ii) Perquisites and Allowances

(iii) Commission (Applicable in case of Executive Directors)

(iv) Retiral benefits

(v) Annual performance Bonus

3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by theNR committee and Annual performance Bonus will be approved by the committee based on theachievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

3.2.1 The Board on the recommendation of the Nomination and Remuneration Committeeshall review and approve the remuneration payable to the Non – Executive Directors ofthe Company within the overall limits approved by the shareholders as per provisions ofthe companies act.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending themeetings of the Board and the Committees thereof.

3.3. Remuneration to other employees

3.3.1.Employees shall be assigned grades according to their qualifications and workexperience competencies as well as their roles and responsibilities in the organization.Individual remuneration shall be determined within the appropriate grade and shall bebased on various factors such as job profile skill sets seniority experience andprevailing remuneration levels for equivalent jobs.

VI. STAKEHOLDERS RELATIONSHIP COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name Designation Category No. of meetings held No. of meeting attended
Ms. P. Chandra Kala Chairman NED(I) 1 1
Mr. S. Nagi Reddy Member ED 1 1
Mr. P. Venkat Ram Reddy Member NED(I) 1 1

NED (I): Non-Executive Independent Director ED: Executive Director

B) Powers:

The Committee has been delegated with the following powers:

• To redress shareholder and investor complaints relating to transfer of sharesDematerialization of Shares non-receipt of Annual Reports non-receipt of declareddividend and other allied complaints.

• To approve transfer transmission and issue of duplicate / fresh sharecertificate(s)

• Consolidate and sub-division of share certificates etc.

• To redress approve and dispose off any other complaints transactions andrequests etc. received from any shareholder of the company and investor in general.

The Board has delegated the power to process the transfer and transmission of shares tothe Registrar and Share Transfer Agents who process share transfers within a week oflodgement in the case of shares held in physical form.

The Company has designated an exclusive e-mail ID called concorddrugsltd@gmail.com forcomplaints/grievances.

VII. RISK MANAGEMENT COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name Designation Category No. of meetings held No. of meeting attended
Ms. P. Chandra Kala Chairman NED(I) - -
Mr. S. Nagi Reddy Member ED - -
Mr. P. Venkat Ram Reddy Member NED(I) - -

NED (I): Non-Executive Independent Director ED: Executive Director

B) RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopteda procedure for assessment and minimization of probable risks. It ensures that all therisks are timely defined and mitigated in accordance with the well-structured riskmanagement process.

12. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

Vigil Mechanism Policy has been established by the Company for directors and employeesto report genuine concerns pursuant to the provisions of section 177(9) & (10) of theCompanies Act 2013 and Regulation 22 of SEBI(LODR) Regulations 2015. The same has beenplaced on the website of the Company.

13. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Companies Act 2013 the Board of Directors to thebest of their knowledge and ability confirm that:

(a) In the preparation of the annual accounts the applicable accounting standards hadbeen followed along with proper explanation relating to material departures;

(b) The Directors had selected such accounting policies and applied them consistentlyand made judgments and estimates that are reasonable and prudent so as to give a true andfair view of the state of affairs of the company at the end of the financial year and ofthe profit and loss of the company for that period;

(c) The Directors had taken proper and sufficient care for the maintenance of adequateaccounting records in accordance with the provisions of this Act for safeguarding theassets of the company and for preventing and detecting fraud and other irregularities;

(d) The Directors had prepared the annual accounts on a going concern basis; and

(e) The Directors had laid down internal financial controls to be followed by thecompany and that such internal financial controls are adequate and were operatingeffectively.

(f) The Directors had devised proper systems to ensure compliance with the provisionsof all applicable laws and that such systems were adequate and operating effectively.

14. INFORMATION ABOUT THE FINANCIAL PERFORMANCE /

FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

The Company does not have any subsidiaries/associates/joint ventures.

15. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED

TO BE ITS SUBSIDIARIES JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

The Company does not have any subsidiaries/associates. During the year neither anyCompany became its subsidiary nor ceased to be its Subsidiary.

16. INVESTOR EDUCTION AND PROTECTION FUND (IEPF):

The Company is not required to transfer any amount to IEPF pursuant to Section 125 ofthe Companies Act 2013 and Rules made thereof.

17. EXTRACT OF ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act 2013 and rule 12(1) of theCompanies (Management and Administration) Rules 2014 an extract of annual return in MGT9 is a part of this Annual Report in enclosed as Annexure-I.

18. STATUTORY AUDITORS:

M/s. N G Rao & Associates Chartered Accountants were appointed as StatutoryAuditors of the company in the 1/2018 Extra ordinary general meeting held on 24th day ofAugust 2018 to fill the casual vacancy caused by the resignation of M/s. MM Reddy &Co. Chartered Accountants Hyderabad and who holds office upto the conclusion of 28thAnnual General Meeting.

19. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS

UNDER SUB SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THECENTRAL GOVERNMENT:

There have been no frauds reported by the auditors' u/s 143(12).

20. SECRETARIAL AUDIT:

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the CompaniesAct 2013 the Board has appointed M/s. Vivek Surana & Associates Practicing CompanySecretaries has under taken Secretarial Audit of the Company for financial year ending31.03.2020.

The report of the Secretarial Auditor is enclosed herewith vide Annexure-II of thisReport.

21. QUALIFICATIONS IN AUDIT REPORTS:

Explanations or comments by the Board on every qualification reservation or adverseremark or disclaimer made—

(a) Statutory Auditors Report:

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the yearended March 31 2020 and has noted that the same does not have any reservationqualification or adverse remarks. However the Board decided to further strengthen theexisting system and procedures to meet all kinds of challenges and growth in the marketexpected in the coming years.

(b) Secretarial Audit Report:

The Board has duly reviewed the Secretarial Audit Report for the year ended March 312020 on the Compliances according to the provisions of section 204 of the Companies Act2013 and the same does not have any reservation qualifications or adverse remarks exceptthe following:

1. Non filing of Form DIR - 12 with ROC pertaining to the appointment of IndependentDirectors in the AGM held on 30.09.2019 and

2. Delay in filing of Listing Application with BSE Ltd. BSE has levied penalty for thesame.

Reply: Reply: The Company has noted the observations and is in the process of complyingthe same.

22. CONSERVATION OF ENERGY TECHNOLOGY ABSORPTION AND

FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 isprovidedhereunder:

A. Conservation of Energy:

Adequate measures have been taken to conserve energy wherever possible by using energyefficient computers and purchase ofenergy efficient equipment.

B. Technology Absorption:

1. Research and Development (R&D): NIL

2. Technology absorption adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings: NIL

Foreign Exchange Outgo: NIL

23. DETAILS RELATING TO DEPOSITS COVERING THE FOLLOWING:

The Company has not accepted any deposits falling within the meaning of Sec.73 74& 76 of the Companies Act 2013 read with the Rule 8(v) of Companies (Accounts) Rules2014 during the financial year under review. Further there are no deposits which are notin compliance with the requirements of Chapter V of the Companies Act 2013.

24. SIGNIFICANT & MATERIAL ORDERS PASSED BY THE

REGULATORS:

During the period under review there were no significant and material orders passed bythe regulators or Courts or Tribunals impacting the going concern status and the company'soperations in future.

25. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Company has well established procedures for internal control across its variouslocations commensurate with its size and operations. The organization is adequatelystaffed with qualified and experienced personnel for implementing and monitoring theinternal control environment. The internal audit function is adequately resourcedcommensurate with the operations of the Company and reports to the Audit Committee of theBoard.

The Board has appointed M/s. PCN & Associates. Chartered Accountants Hyderabad asInternal Auditors in its meeting held 14.08.2019 for the year 2019-20. Summary ofsignificant Audit observations along with recommendations and its implementations arereviewed by the Audit committee and concerns if any are reported to Board.

26. INSURANCE:

The properties and assets of your Company are adequately insured.

27. RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopteda procedure for assessment and minimization of probable risks. It ensures that all therisks are timely defined and mitigated in accordance with the well-structured riskmanagement process.

28. PARTICULARS OF LOANS GUARANTEES OR INVESTMENTS:

The company has not given loans Guarantees or made any investments covered undersection 186 of Companies Act 2013 during the year under review.

29. CREDIT & GUARANTEE FACILITIES:

The Company is availing Credit and Guarantee Facilities from State Bank of IndiaDilsukhnagar Branch.

30. SHARE CAPITAL

The authorised share capital of the Company stands at Rs. 110000000/- divided into11000000 equity shares of Rs.10/- each.

The paid up share capital of the Company stands at Rs. 87437500 /- divided into8743750 equity shares of Rs.10/- each.

31. COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR

POLICY:

Since the Company does not have the net worth of Rs. 500 Crore or more or turnover ofRs. 1000 Crore or more or a net profit of Rs. 5 Crore or more during the financial yearsection 135 of the Companies Act 2013 relating to Corporate Social Responsibility is notapplicable and hence the Company need not adopt any Corporate Social ResponsibilityPolicy.

32. RELATED PARTY TRANSACTIONS:

All contracts/arrangements/transactions entered by the Company during the financialyear with related parties were in the ordinary course of business and on arm's lengthbasis. There were no material significant related party transactions made by the Companywith the Promoters Directors Key Managerial Personnel or the Senior Management which mayhave a potential conflict with the interest of the Company at large.

All related party transactions were placed before the Audit Committee/Board forapproval. Prior approval of the Audit Committee was obtained for the transactions whichare foreseen and are in repetitive in nature.

Transactions with the Related Parties as required under Indian Accounting Standard-18are disclosed in Note 2.4 of the standalone financial statements forming part of thisAnnual Report

33. POLICIES

The SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 mandatedthe formulation of certain policies for all listed companies. All the policies areavailable on our website (www.concorddrugs.in). The policies are reviewed periodically bythe Board and updated based on need and new compliance requirement.

34. DISCLOSURE ABOUT COST AUDIT:

The Company is in due compliance with the Companies (Cost Records and Audit) Rules2014. M/s KJU & Associates Cost Accountants is the Cost Auditors of the Company.

35. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act 2013 and Rule 5(1)(2) & (3) of theCompanies (Appointment & Remuneration) Rules 2014 the ratio of remuneration of Mr.Nagi Reddy Chairman & Whole-time Director & Mr. Koni Reddy (Director cum CFO) tomedian employees is 9.09:1 & 9.09:1 time respectively.

36. C O R P O R AT E G O V E R N A N C E A N D S H A R E H O L D E R S

INFORMATION:

Since the paid-up capital of the Company is less than Rs. 10 Crores and Net worth ofthe Company is less than Rs. 25 Crores Corporate Governance as envisaged in SEBI (LODR)Regulations is not applicable.

37. SECRETARIAL STANDARD

The Company is in compliance with the applicable secretarial standards SS1 and SS2

38. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED

UNDER THE INSOLVENCY AND BANKRUPTCY CODE 2016 (IBC):

There is no application filed for corporate insolvency resolution process by afinancial or operational creditor or by the company itself under the IBC before the NCLT

39. EVENT BASED DISCLOSURES

During the year under review the Company has taken up any of the following activities:

1. Issue of sweat equity share: NA

2. Issue of shares with differential rights: NA

3. Issue of shares under employee's stock option scheme: NA

4. Disclosure on purchase by company or giving of loans by it for purchase of itsshares: NA

5. Buy back shares: NA

6. Disclosure about revision: NA

7. Preferential Allotment: However the Company has allotted 882000 equity shares on atpar to the promoters and others on preferential Basis on 14.05.2019 on conversion ofwarrants.

40. NON-EXECUTIVE DIRECTORS' COMPENSATION AND

DISCLOSURES

None of the Independent / Non-Executive Directors has any pecuniary relationship ortransactions with the Company which in the Judgment of the Board may affect theindependence of the Directors.

41. CEO/ CFO Certification

The Managing Director and CFO certification of the financial statements for the year2019-20 is annexed in this Annual Report.

42. STATEMENT SHOWING THE NAMES OF THE TOP TEN

EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE5(2) & (3)OF THE COMPANIES(APPOINTMENT & REMUNERATION) RULES 2014:

A table containing the particulars in accordance with the provisions of

Section 197(12) of the Act read with Rule 5(2) of the Companies (Appointment andRemuneration of Managerial Personnel) Rules 2014 is appended as Annexure III to thisReport.

A statement showing the names of the top ten employees in terms of remuneration drawnand the name of every employee is annexed to this Annual report as Annexure IV.

During the year NONE of the employees is drawing a remuneration of Rs.10200000/- andabove per annum or Rs.850000/- and above in aggregate per month the limits specifiedunder the Section 197(12) of the Companies Act2013 read with Rules 5(2) and 5(3) of theCompanies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

43. BOARD EVALUATION:

Pursuant to the applicable provisions of the Companies Act 2013 and SEBI ListingRegulations the Board has carried out an Annual Evaluation of its own performanceperformance of the Directors and the working of its Committees. The Board's functioningwas evaluated on various aspects including inter alia degree of fulfilment of keyresponsibilities Board structure and composition establishment and delineation ofresponsibilities to various Committees effectiveness of Board processes information andfunctioning.

Evaluation of the Committees performance was based on the criteria like compositionits terms of the reference and effectiveness of committee meetings etc. IndividualDirector's performance evaluation is based on their preparedness on the issues to bediscussed meaningful and constructive discussions and their contribution to the Board andCommittee meetings. The Chairperson was evaluated mainly on key aspects of his role. Theseperformance exercises were conducted seeking inputs from all the Directors / CommitteeMembers wherever applicable.

The evaluation procedure followed by the company is as mentioned below:

i) Feedback is sought from each Director about their views on the performance of theBoard covering various criteria such as degree of fulfilment of key responsibilitiesBoard structure and composition establishment and delineation of responsibilities tovarious Committees effectiveness of Board processes information and functioning Boardculture and dynamics quality of relationship between the Board and the Management andefficacy of communication with external stakeholders.

Feedback was also taken from every Director on his assessment of the performance ofeach of the other Directors.

ii) The Nomination and Remuneration Committee (NRC) then discusses the above feedbackreceived from all the Directors.

iii) Based on the inputs received the Chairman of the NRC also makes a presentation tothe Independent Directors at their meeting summarising the inputs received from theDirectors as regards Board performance as a whole and of the Chairman. The performance ofthe Non-Independent Non-Executive Directors and Board Chairman is also reviewed by them.

iv) Post the meeting of the Independent Directors their collective feedback on theperformance of the Board (as a whole) is discussed by the Chairman of the NRC with theChairman of the Board. It is also presented to the Board and a plan for improvement isagreed upon and is pursued.

v) Every statutorily mandated Committee of the Board conducts a self-assessment of itsperformance and these assessments are presented to the Board for consideration. Areas onwhich the Committees of the Board are assessed include degree of fulfilment of keyresponsibilities adequacy of Committee composition and effectiveness of meetings.

vi) Feedback is provided to the Directors as appropriate. Significant highlightslearning and action points arising out of the evaluation are presented to the Board andaction plans are drawn up. During the year under report the recommendations made in theprevious year were satisfactorily implemented.

The peer rating on certain parameters positive attributes and improvement areas foreach Board member are also provided to them in a confidential manner. The feedbackobtained from the interventions is discussed in detail and where required independentand collective action points for improvement are put in place.

44. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING

The Company has also adopted a code of conduct for prevention of Insider trading. Alldirectors senior management employees and other employees who are having access to theunpublished price sensitive information of the company are governed by the code. TheInsider Trading Policy of the Company lays down guidelines and procedures to be followedand disclosures to be made while dealing with shares of the Company as well as theconsequences of violation. The policy has been formulated to regulate monitor and ensurereporting of deals by employees and to maintain the highest ethical standards of dealingin Company securities.

During the year under the review there has been due compliance with the code of conductfor prevention of insider trading. The code of conduct for prevention of insider tradingis available in the company's website www.concorddrugs.in

45. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT

WORKPLACE (PREVENTION PROHIBITION AND REDRESSAL) ACT 2013

The Company has in place an Anti-Sexual Harassment Policy in line with the requirementsof The Sexual Harassment of Women at workplace (Prevention Prohibition and Redressal)Act 2013. Internal Complaint Committee (ICC) has been set up to redress complaintsreceived regarding sexual harassment. All employees are covered under this policy. Thefollowing is the summary of sexual harassment complaints received and disposed during thecalendar year.

• No. of complaints at the beginning of the year: Nil

• No. of complaints received: Nil

• No. of complaints disposed off: Nil

46. DETAILS OF PENALITIES IMPOSED BY THE REGULATORY

AUTHORITIES

During the year under review BSE has levied the penalty for delay in filing theapplication for the listing approval of 882000 equity shares and the company is yet topay the penalty.

47. INVESTOR EDUCATION AND PROTECTION FUND

No amounts and/or shares were transferred to the Investor Education and Protection Fundduring the year under review.

48. DISCLOSURE ON CORPORATE INSOLVENCY RESOLUTION

PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE.

No corporate insolvency resolution process was initiated under the provisions ofInsolvency and Bankruptcy Code during the year under review.

49. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fullycommitted to its social responsibility. The Company has been taking upmost care incomplying with all pollution control measures from time to time strictly as per thedirections of the Government.

We would like to place on record our appreciation for the efforts made by themanagement and the keen interest shown by the Employees of your Company in this regard.

50. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliancewith regard to the affairs of the Company in all respects

51. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report pursuant to the SEBI (LODR) Regulationappended as Annexure V for information of the Members.

52. ACKNOWLEDGEMENTS:

The Directors wish to place on record their appreciation of the contribution made bythe employees at all levels to the continued growth and prosperity of your Company.

The Directors also wish to place on record their appreciation of business constituentsbanks and other financial institutions and shareholders of the Company for their continuedsupport for the growth of the Company.

For and on behalf of the Board
For Concord Drugs Limited
Sd/- Sd/-
S. Nagi Reddy T. Narsimha Reddy
Chairman Managing Director
(DIN: 01764665) (DIN: 07538313)

Place: Hyderabad Date : 27.06.2020

Certificate of Code of Conduct for the year 2019-20

To

The shareholders

Concord Drugs Limited

Code of Conduct

The Company has formulated and implemented a Code of Conduct for Board Members andSenior Management of the Company. Requisite annual affirmations of compliance with therespective Codes have been made by the Directors and Senior Management of the Company.

Certificate of Code of Conduct for the year 2019-2020 as per Regulation 17(5) read withRegulation 34 (3) Schedule V of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015.

Concord Drugs Limited is committed for conducting its business in accordance with theapplicable laws rules and regulations and with highest standards of business ethics. TheCompany has adopted a "Code of Ethics and Business Conduct" which is applicableto all Director officers and employees.

I hereby certify that all the Board Members and Senior Management have affirmed thecompliance with the Code of Ethics and Business Conduct under a certificate of Code ofConduct for the year 2019-20

For and on behalf of the Board For Concord Drugs Limited

Sd/-S. Nagi Reddy Chairman (DIN: 01764665)

Place: Hyderabad Date : 27.06.2020

CERTIFICATE BY THE MANAGING DIRECTOR AND CFO OF THE COMPANY

To

The Board of Directors

Concord Drugs Limited

Dear Sirs

As required under Regulation 17(8) read with Part B Schedule II of SEBI (ListingObligations and Disclosure Requirements) Regulations 2015 we state that:

1. We have reviewed the financial statements and the cash flow statement for the yearended 31st March 2020 and to the best of our knowledge and belief;

a. These statements do not contain any materially untrue statement nor omit anymaterial fact nor contain statements that might be misleading and

b. These statements present a true and fair view of the company's affairs and are incompliance with the existing accounting standards applicable laws and regulations.

2. There are to the best of my knowledge and belief no transactions entered into bythe company during the year which are fraudulent illegal or violative of the company'scode of conduct.

3. We accept responsibility for establishing and maintaining internal controls I haveevaluated the effectiveness of the internal control systems of the company and I havedisclosed to the auditors and the audit committee deficiencies in the design or theoperation of internal controls if any of which I was aware and the steps that I havetaken or propose to take and rectify the identified deficiencies and

4. That we have informed the auditors and the audit committee of: a) Significantchanges in the internal control during the year;

b) Significant changes in accounting policies during the year and that the same havebeen disclosed in the notes to the financial statements; and

c) Instances of significant fraud of which we have become aware and the involvement ofany employee having a significant role in the company's internal control system.

For and on behalf of the Board
Concord Drugs Limited
Sd/- Sd/-
T. Narsimha Reddy S. Koni Reddy
Managing Director Director & CFO

Place: Hyderabad Date: 27.06.2020

DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACOUNT

As per Regulation 34(3) read with Schedule V of SEBI (Listing Obligations andDisclosure Requirements) Regulations 2015 the company hereby discloses the details ofunpaid/unclaimed dividend and the respective share thereof as follows:

Aggregate No. of Shareholders and the outstanding shares in the suspense account at the beginning of the year. No. of shareholders who approached the company for transfer of shares from suspense account during the year. No. of shareholders to whom shares were transferred from suspense account during the year. Aggregate No. of Shareholders and the outstanding shares in the suspense account at the end of the year.
NIL NIL NIL NIL

 

** Voting Right on these shares shall remain frozen till the rightful owner of suchshares claims the shares.

Note: The Company has never declared dividends since its inception and therefore thereis no amount lying in unpaid/unclaimed dividend account.

MGT 9

Extract of Annual Return

As on the Financial Year 31.03.2020

[Pursuant to section 92(3) of the Companies Act 2013 and rule 12(1) of the Companies(Management and Administration) Rules 2014]

:

i.
ii. Registration Date 24/04/1995
iii. Name of the Company Concord Drugs Limited
iv. Category / Sub-Category of the Company Company limited by Shares/Non-govt company
v. Address of the Registered details Survey No.249 Brahmanapally Village HayatnagarMandal R. R District 501511Telangana
vi. Whether listed company Yes / No Yes
vii. Name Address and Contact details of Registrar and Transfer Agent if any Aarthi Consultants Pvt. Ltd1-2-285 DomalagudaHyderabadTelangana500029 Tel: 040-27634445
Fax: 040-27634445
Email: info@aarthiconsultants.com

All the business activities contributing 10 % or more of the total turnover of thecompany shall be stated:-

Sl. No. Name and Description of main products /services Product / service % to total turnover of the company
1 Pharmaceuticals 2423 100.0
S.N o. Name and Address of the Company Holding/Subsidiary /Associate % of shares held Applicable Section
The Company does not have any subsidiaries.

i) Category-wise Share Holding;-

Category of Sharehold ers

No. of Shares held at the beginning of the year

No. of Shares held at the end of the year

%Change during the year

Demat Physical Total % of Total Shares Demat Physical Total % of Tot al Sh are s
A. Promoters
(1)Indian Individual/ 3058500 0 305850 0 38.41 305850 0 6820 00 3740500 42. 78 4.2 7
Central Govt. -- -- -- -- -- -- -- -- --
State Govt .(s) -- -- -- -- -- -- -- -- --
Bodies Corp. -- -- -- -- -- -- -- -- --
Banks / FI -- -- -- -- -- -- -- -- --
Any Other…. -- -- -- -- -- -- -- -- --
Sub-total 3058500 0 3058500 38.41 3058500 682000 3740500 42. 4.27
(A) (1) :- 78
(2) Foreign
- -- -- -- -- -- -- -- -- --
Individuals
b) Other – -- -- -- -- -- -- -- -- --
Individuals
c) Bodies -- -- -- -- -- -- -- -- --
Corp.
d) Banks / -- -- -- -- -- -- -- -- --
e) Any -- -- -- -- -- -- -- -- --
Other….
Sub-total (A) (2):- -- -- -- -- -- -- -- -- --
Total shareholdin g of Promoter (A) =(A)(1)+(A)( 2) 3058500 0 305850 0 38.41 305850 0 6820 00 3740500 42. 78 4.2 7
B. Public
Shareholdin g
1.Institution s
a) Mutual Funds -- -- -- -- -- -- -- -- --
b) Banks / -- -- -- -- -- -- -- -- --
c) Central Govt -- -- -- -- -- -- -- -- --
d) State Govt(s) -- -- -- -- -- -- -- -- --
e) Venture Capital Funds -- -- -- -- -- -- -- -- --
f) Insurance -- -- -- -- -- -- -- -- --
Companies -- -- -- -- -- -- -- -- --
h) Foreign Venture Capital Fund -- -- -- -- -- -- -- -- --
Sub-total (B1) -- -- -- -- -- -- -- -- --
2. Non Institutions
a) Bodies Corp.
i) Indian 76552 0 76552 0.97 14849 0 14849 0.1 7 (0.8 0)
ii) Overseas -- -- -- -- -- -- -- -- --
b) Individuals
i) Individual shareholder s holding nominal share capital up to Rs. 1 lakh 1449747 557000 2006747 25.53 1456965 55500 0 1911965 21. 87 1.4 5
ii) Individual shareholder s holding nominal share capital inexcess of Rs 1lakh 2803062 0 2803062 35.65 2639446 40270 0 3042146 32. 50 0.0 5
c) Others (specify) 35569 0

35569

0.45

34049 0 34049 0.3 9 (0.0 6)
2. Clearing Members 13425 0 13425

0.17

241 0 241 0.0 0 (0.1 7)
Sub-total (B)(2):- 3966898 759800 4726698 60.12 4045550 95770 0 5003250 57. 22 0.3 1
Total Public 61.10 4045550 95770 5003250 57.
Shareholdin g 4043450 759800 480325 0 0 22 0.3 1
(B)=(B)(1)+( B)(2)
C. Shares held by Custodian -- -- -- -- -- -- -- -- --
Grand Total (A+B+C) 7290150 571600 786175 0 100 7104050 16397 00 8743750 100 .00 --

(ii)Shareholding of Promoters

Sl N o Name

No. of Shares held at the beginning of the year

No. of Shares held at the end of the year

%Change during the year
No. of shares % of TotalShares of the company % of shares pledge d/encu mbere d to total shares No. of shares % of Total Shares of the compan y % of shar es pled ged/ encu mber ed to total shar es
1. S.Nagi Reddy 1413000 17.98 -- 17030 00 19.48 -- 1.50
2. S.Koni Reddy 797000 10.14 --

975000

11.15

-- 1.01
3. VundelaRamasu bba Reddy 397500 5.06 -- 397500 5.06 -- 0.00
4. S. Manoj Kumar Reddy 451000 5.74 -- 665000 7.61 -- 1.87

(iii) No Change

Sl. No. Shareholding at the beginning of the year

Cumulative Shareholding during the year

No. of Shares % of total shares of the company No. of shares % of total shares of the company
1 S. Nagi Reddy 1413000 17.97
Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc): Increase in shareholding : conversion of shares into warrants 290000 1.51
At the End of the year -- -- 1703000 19.48
2 S. Koni Reddy 797000 10.14
Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc): Increase in shareholding : conversion of shares into warrants 178000 1.01
At the End of the year -- -- 975000
3 S. Manoj Kumar Reddy 451000 5.74
Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc): Increase in shareholding : conversion of shares into warrants 214000 1.87 -- --
At the End of the year -- -- 665000 7.61
4 Vundela Ramasubba Reddy 397500 5.06
Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc): -- -- -- --
At the End of the year 397500 5.06

(iv) Shareholding Pattern of top ten Shareholders (other than Directors Promotersand Holders of

Shareholding at the beginning of the year

Increase/

Cumulative Shareholding during the year

Sl. No Name of Shareholder . No. of Shares % of total Shar es of the Com pany Date Decrease in sharehold ing Reason No. of Shares % of total Shares of the Company
1. P. Lakshmi - - 14.05.2019 200000 2.29 200000 2.29
2 Rajender Kumar Agarwal 167633 2.13 -- -- -- 167633 2.13
20.12.2019 1000 purchas e 168633
3 Puttaha Mahesh Kumar 166000 -- -- -- 166000
4 Sushil Kumar Agarwal 130400 1.66 -- -- -- 130400 1.66
5 Manju Agarwal 130140 1.65 -- -- -- 130140 1.65
6 Sanivarapu Jhansi 125560 1.60 -- -- -- 125560 1.60
7. S.N. Thulasi Devi 121200 1.54 -- -- -- 121200 1.54
8 Sannuthi Lokesh 100000 1.27 -- -- -- 100000 1.27
9 Chandra mounika Sannuthi 100000 1.27 -- -- -- 100000 1.27
10 Rakesh K 100000 1.27 -- -- -- 100000 1.27

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No. For Each of the Directors Shareholding at the beginning of the year

CummulativeShare Holding during the year

1. No. of Shares % of total shares of the company No. of shares % of total shares of the company
At the beginning of the year 1413000 17.97
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc): Increase in shareholding : conversion of shares into warrants 290000 1.51
At the End of the year -- -- 1703000 19.48
2 S. Koni Reddy 797000 10.14
At the beginning of the year Increase in shareholding : conversion of shares into warrants 178000 1.01
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons -- -- 975000 11.15
for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):
At the End of the year 1413000 17.97
3.
At the beginning of the year 50000 0.69
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc): -- -- --
At the End of the year -- -- 50000 0.69
4. -- -- -- --
At the beginning of the year -- -- -- --
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc): -- -- --
At the End of the year -- -- -- --
6. Ms. P. Chandra Kala -- -- -- --
At the beginning of the year -- -- -- --
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc): -- -- -- --
At the End of the year -- -- -- --
7. -- -- -- --
At the beginning of the year -- -- -- --
Date wise Increase /Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc): -- -- -- --
At the End of the year -- -- -- --

V

Indebtedness of the Company including interest outstanding/accrued but not due forpayment

Indebtedness at the beginning of the Secured Loans excluding deposits Unsecured Loans Deposits Total Indebtedness
Principal Amount 97963838 5731354 -- 103695192
ii) Interest due but not paid
iii) Interest accrued but not due
Total (i+ii+iii) 97963838 5731354 -- 103695192
Change in (4511056) 1050926 -- (3460130)
Indebtedness during
Addition Reduction
Net Change (4511056) 1050926 -- (3460130)
Indebtedness at the 93452782 6782280 -- 100235062
i) Principal Amount ii) Interest due but not paid iii) Interest accrued but not due
Total (i+ii+iii) 93452782 6782280 -- 100235062

 

A. Remunerat -time Directors and/or Manager:

Sl. no. Particulars of Remuneration

S. Nagi Reddy

Koni Reddy Total Amount
1. Gross salary

Remuneration to managing Director

Remuneration to Whole- time Director 2400000
(a) Salary as per provisions contained in section 17(1) of the Income-tax Act 1961 1200000

1200000

(b) Value of perquisites u/s 17(2) Income-tax Act 1961 under section 17(3) Income tax Act 1961
2. Stock Option

--

--
3. Sweat Equity

--

--
4. Commission

--

--
- Others specify…
5. Others please specify

--

--
Total (A)

1200000

1200000 2400000
Ceiling as per the Act

6000000

6000000 --

 

B. Remuneration to other directors:

Sl. no. Particulars of Remuneration

Name of Director

Total Amount
1. Independent Directors -- -- -- -- --
Fee for attending board / committee meetings
Commission Others please specify
Total (1) -- -- -- -- --
2. Other Non-Executive Directors Fee for attending board / committee meetings commission Others please specify -- -- -- -- --
Total (2) -- -- -- -- --
Total (B)=(1+2) -- -- -- -- --
Total Managerial Remuneration -- -- -- -- --
Overall Ceiling as per the Act -- -- -- -- --
Sl. no. Particulars of Remuneration

Key Managerial Personnel

Company Secretary Jyoti Goyal S. Koni Reddy Total
1. Gross salary -- -- 1375
(a) Salary as per provisions contained in section 17(1) of the Income-tax Act 1961 137500 00
(b) Value of perquisites u/s 17(2) Income-tax Act 1961 17(3) Income-tax Act 1961
2. Stock Option
3. Sweat Equity
4. Commission
-
- others specify…
5. Others please
Specify
6. Total -- 137500 1375
00
Companies Act Description Penalty / Punishment/ Compounding fees imposed made if any (give Details)
Penalty -- -- -- -- --
Punishment -- -- -- -- --
Compounding -- -- -- -- --
Penalty -- -- -- -- --
Punishment -- -- -- -- --
Compounding -- -- -- -- --
Penalty -- -- -- -- --
Punishment -- -- -- -- --
Compounding -- -- -- -- --

.